TB Clip February 2022 article image

편집자 한마디!

국내외 결핵(TB)뉴스

학술연구자료

STOP - TB 코리아 소식

대규모 관찰연구인 endTB Cohort에서 BDQ 및 DLM을 포함하는 장기간의 MDR/RR-TB 요법의 안전성을 평가한 결과를 발표하였습니다.
2,296명의 환자 (median age, 36; HIV co-infection in 13.8%, cavitary disease in 60.9%, and XDR-TB in 29.7%) 중 치료 요법에는 LZD 79.5%, 주사제 40.3%, BDQ 71.0%, DLM 39.4%, BDQ+DLM 10.4%가 포함되었습니다. 가장 흔한 부작용으로는 말초신경병증(26.4%), 전해질 고갈(26.0%), 난청(13.2%)이었으며, QT간격 연장은 참가자의 2.7%에서만 관찰 되었습니다. LZD 및 주사제와 관련된 이상반응은 BDQ 및 DLM 의한 이상반응보다 더 흔했으며, MDR-TB 치료 모니터링 일정 및 각 약물 투약 기간은 약물 조합의 예상되는 안전성 프로파일이 반영되어야 한다고 결론지었습니다.

In an effort to increase attention about TB with the general population, the Stop TB Partnership launched awareness efforts at the heart of New York City at Times Square. “We want to make sure that people understand that this is an airborne disease which kills three people every 15 seconds. No, it is not COVID-19. It is Tuberculosis. We need focus and considerable investments if we are to end this deadly disease.”

Following review of evidence and advice from the Technical Advisory Group on TB Diagnostics and Laboratory Strengthening, the World Health Organization (WHO) announced that current WHO recommendations for the use of interferon-gamma release assays (IGRA) are also valid for Beijing Wantai’s TB-IGRA and Qiagen QuantiFERON-TB Gold Plus products. Full details are provided in the WHO policy statement.

Policy Cures Research released the G-FINDER 2021 report analyzing research and development (R&D) funding trends for neglected diseases. The report showed that global investments in TB R&D funding totaled $684 million in 2020 - far short of the estimated $2.16 billion needed annually to develop and deliver new tools that can end TB. The press release announcing the report can be accessed here.

According to a multicenter, prospective observational study published in Clinical Infectious Diseases, among patients with multidrug-resistant TB, adverse events related to treatment with linezolid and injectable drugs were found to be more common compared with those related to bedaquiline and delamanid.

Researchers discovered a molecule in the lungs of TB patients that reflects the levels of TB-causing bacteria in the lungs. The findings, published in the Journal of Clinical Investigation, could be a step toward more tailored treatment regimens and better outcomes for TB patients.

According to results published in Clinical Infectious Diseases, a Phase 3 randomized trial found that daily treatment with high-dose rifapentine for TB decreased efavirenz clearance and achieved therapeutic targets among patients coinfected with HIV receiving efavirenz-based antiretroviral therapy.

In a study, published in Advanced Healthcare Materials, researchers presented a new fluorescent probe for detecting TB that can now identify disease-causing bacteria in extra-pulmonary tissue for better diagnosis.

A new vaccine against TB may also be used as treatment. A new study, published in Nature Communications, showed that the vaccine was safe to give to people with TB disease and strengthened the immune system's ability to attack the bacteria that cause the disease.

A retrospective analysis, published in Pathogens, highlighted technological pediatric TB research advances across the TB care cascade; discussed recently completed or ongoing work in adults and corresponding significant research gaps for children; and offered recommendations and opportunities to increase investments and accelerate pediatric TB research and development.

The International Union Against Tuberculosis and Lung Disease released the February 2022 issue of the International Journal of Tuberculosis and Lung Disease (IJTLD). It includes TB-related research publications.

RESIST-TB released its January 2022 newsletter with the latest research publications on drug-resistant TB.